Active Ingredient History

  • Now
Sprifermin (INN), is a recombinant human fibroblast growth factor 18 (rhFGF18) analog, which is under development by Merck and Nordic Bioscience for the treatment of osteoarthritis. FGF18 and sprifermin are potent agonists of the FGFR2, FGFR3 and FGFR4.   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
as902330 | fgf-18 | fgf-18 protein, human | fgf18 protein, human | fgf-18 protein, mouse | fgf18 protein, mouse | fgf-18 protein, rat | fgf18 protein, rat | fibroblast growth factor 18 | fibroblast growth factor 18, human | fibroblast growth factor 18, mouse | fibroblast growth factor 18, rat | sprifermin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue